{"disease":{"id":"irritable-bowel-syndrome-characterized-by-constipation","name":"Irritable bowel syndrome characterized by constipation","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":5,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"azd1722","indication_name":"Irritable bowel syndrome characterized by constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ibsrela","generic_name":"AZD1722","company_name":"Ardelyx Inc","drug_phase":"marketed","molecular_target":"Sodium/hydrogen exchanger 3","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Ibsrela works by inhibiting the sodium/hydrogen exchanger 3, a protein that regulates the balance of sodium and hydrogen ions in the gut."},{"drug_id":"linaclotide","indication_name":"Irritable bowel syndrome characterized by constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Linzess","generic_name":"LINACLOTIDE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Heat-stable enterotoxin receptor","drug_class":"Guanylate Cyclase-C Agonist [EPC]","quality_score":57,"revenue":null,"mechanism":"Linzess works by activating the heat-stable enterotoxin receptor to increase fluid secretion in the intestines."},{"drug_id":"linzess","indication_name":"Irritable bowel syndrome characterized by constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Linzess","company_name":"TriHealth Inc.","drug_phase":"discontinued","molecular_target":"Heat-stable enterotoxin receptor, Heat-stable enterotoxin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"lubiprostone","indication_name":"Irritable bowel syndrome characterized by constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amitiza","generic_name":"LUBIPROSTONE","company_name":"Sucampo Pharma Llc","drug_phase":"marketed","molecular_target":"Chloride channel protein 2","drug_class":"Chloride Channel Activator [EPC]","quality_score":65,"revenue":null,"mechanism":"Amitiza works by activating chloride channels in the intestines, increasing fluid secretion and promoting bowel movements."},{"drug_id":"tegaserod","indication_name":"Irritable bowel syndrome characterized by constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zelnorm","generic_name":"TEGASEROD","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2B","drug_class":"Serotonin-4 Receptor Agonist","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03573908","title":"A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":614,"lead_sponsor_name":"Ironwood Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02837783","title":"A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Ironwood Pharmaceuticals, Inc.","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}